Valerio Therapeutics agrees €30 million Etherna acquisition alongside €40.25 million financing
- nuaxia
- 8시간 전
- 3분 분량
The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.
Valerio Therapeutics has signed definitive agreements to acquire 100% of Etherna Immunotherapies based on an enterprise value of €30 million, funded through a combination of cash and shares, alongside a €40.25 million PIPE financing from new and existing investors.
The acquisition brings together Valerio’s nucleic acid chemistry and targeted moiety engineering with Etherna’s mRNA, lipid nanoparticle delivery and manufacturing capabilities, supporting development of RNA medicines targeting tissues beyond the liver.
Field | Content |
Alert Type | Deal |
Companies | Valerio Therapeutics; Etherna Immunotherapies |
Deal Type | Acquisition |
Asset or Company | 100% of Etherna Immunotherapies NV |
Therapy Area(s) | Multiple; initial proprietary programmes include immunological indications |
Technology or Modality | mRNA; lipid nanoparticles (LNPs); nucleic acid chemistry; targeted RNA delivery; GMP manufacturing |
Deal Value | The acquisition is based on an enterprise value of €30 million, on a debt-free, cash-free basis and subject to customary adjustments and contingent earn-out payments. Consideration comprises cash and Valerio shares. Separately, Valerio has priced a €40.25 million PIPE financing to fund the cash component and support development of the combined company; the financing should not be treated as acquisition consideration. |
Development Stage | Platform and preclinical pipeline; Valerio intends to use financing proceeds to advance VTX-001, VTX-002 and VTX-003, including IND-enabling activities for VTX-001. |
Geography | France; Belgium; global development and partnering scope |
What Happened | On 24 August 2026, Valerio Therapeutics announced definitive agreements to acquire 100% of Etherna Immunotherapies for an enterprise value of €30 million, following the binding offer announced in July. The consideration comprises cash, funded through the PIPE, and Valerio shares issued in exchange for Etherna shares. Valerio simultaneously priced a €40.25 million PIPE through the issuance of 68,220,333 new shares at €0.59 per share. The share consideration remains subject to approval at an extraordinary general meeting expected around 6 October 2026; shareholders representing more than 70% of voting rights have provided irrevocable voting undertakings supporting the transaction. |
Why It Matters | Etherna adds established mRNA chemistry, customised LNP delivery and in-house GMP manufacturing to Valerio’s targeted RNA capabilities. Combining these technologies gives Valerio greater control across discovery, delivery and manufacturing and is intended to support development of nucleic acid medicines targeting tissues beyond the liver, an important technical challenge for expanding RNA therapeutics into additional diseases. |
Supporting Context | Etherna has more than a decade of experience developing mRNA and LNP technologies and provides platforms and manufacturing services to pharmaceutical and biotechnology partners. Valerio’s strategy centres on precision-guided RNA therapeutics using complementary nucleic acid chemistry and targeted delivery technologies. |
Strategic Rationale | Valerio gains Etherna’s mRNA and LNP technologies, technical expertise and GMP manufacturing infrastructure, creating a more vertically integrated RNA development platform. Financing proceeds are expected to support integration and expansion of Etherna’s Niel manufacturing facility alongside advancement of Valerio’s proprietary pipeline. |
Potential Impact | Successful integration could enable Valerio to move targeted RNA programmes from discovery towards clinical development with greater internal control over delivery, CMC and manufacturing. The combined capabilities could also support future partnering and licensing opportunities, although their clinical and commercial value will depend on successful programme development. |
Key Takeaway | The €30 million Etherna acquisition gives Valerio an integrated mRNA, LNP and manufacturing platform, while the accompanying €40.25 million financing provides capital to combine the businesses and advance its targeted RNA pipeline. |
What to Watch | Shareholder approval of the share consideration, completion of the acquisition, integration and expansion of Etherna’s GMP manufacturing capabilities, and progress of VTX-001 towards IND-enabling development. |
Primary Source | |
Relevant Date | 24 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글